Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amylyx Pharmaceuticals Inc (AMLX)

Amylyx Pharmaceuticals Inc (AMLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,371,652
  • Shares Outstanding, K 109,820
  • Annual Sales, $ 87,370 K
  • Annual Income, $ -301,740 K
  • EBIT $ -157 M
  • EBITDA $ -166 M
  • 60-Month Beta -0.34
  • Price/Sales 15.47
  • Price/Cash Flow N/A
  • Price/Book 4.07

Options Overview Details

View History
  • Implied Volatility 81.54% (+15.46%)
  • Historical Volatility 53.73%
  • IV Percentile 33%
  • IV Rank 7.57%
  • IV High 422.03% on 01/14/25
  • IV Low 53.64% on 08/29/25
  • Expected Move (DTE 22) 1.33 (10.68%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 20
  • Volume Avg (30-Day) 68
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 8,334
  • Open Int (30-Day) 8,957
  • Expected Range 11.16 to 13.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.30
  • Number of Estimates 5
  • High Estimate -0.14
  • Low Estimate -0.37
  • Prior Year -0.55
  • Growth Rate Est. (year over year) +45.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.69 +6.84%
on 12/17/25
15.24 -18.04%
on 11/28/25
-2.33 (-15.72%)
since 11/24/25
3-Month
11.69 +6.84%
on 12/17/25
16.96 -26.36%
on 10/21/25
-1.39 (-10.01%)
since 09/24/25
52-Week
2.60 +380.38%
on 03/04/25
16.96 -26.36%
on 10/21/25
+8.49 (+212.25%)
since 12/24/24

Most Recent Stories

More News
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

- AMX0114 was generally well-tolerated, with no treatment-related serious adverse events - Amylyx will proceed with opening enrollment of second cohort ...

AMLX : 12.49 (+1.46%)
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

AMLX : 12.49 (+1.46%)
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). ...

AMLX : 12.49 (+1.46%)
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). ...

AMLX : 12.49 (+1.46%)
Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

Completion of recruitment for pivotal Phase 3 LUCIDITY trial of avexitide expected in Q1 2026, with topline data anticipated in Q3 2026 Cash runway expected...

AMLX : 12.49 (+1.46%)
Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will present at the following upcoming conferences, which are being conducted in-person: ...

AMLX : 12.49 (+1.46%)
Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its third quarter 2025 financial results on Thursday, November 6, 2025. Amylyx’ senior management team...

AMLX : 12.49 (+1.46%)
Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

AMLX : 12.49 (+1.46%)
Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

AMLX : 12.49 (+1.46%)
Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

AMLX : 12.49 (+1.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amylyx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It focuses on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 13.11
2nd Resistance Point 12.90
1st Resistance Point 12.69
Last Price 12.49
1st Support Level 12.27
2nd Support Level 12.06
3rd Support Level 11.85

See More

52-Week High 16.96
Last Price 12.49
Fibonacci 61.8% 11.47
Fibonacci 50% 9.78
Fibonacci 38.2% 8.09
52-Week Low 2.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar